BRAFSerine/threonine-protein kinase B-raf
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable).
UniProt locations Nucleus · Cytoplasm · Cell membrane
Function
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway [20, 33]. Phosphorylates PFKFB2 [29].
May play a role in the postsynaptic responses of hippocampal neurons [1]
Evidence & references
- ECO:0000269 PubMed:1508179 ↗
- ECO:0000269 PubMed:21441910 ↗
- ECO:0000269 PubMed:29433126 ↗
- ECO:0000269 PubMed:36402789 ↗
- ECO:0000305
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "1508179"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21441910"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "29433126"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "36402789"
},
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)"
}
],
"commentType": "FUNCTION"
}Catalytic activity
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+)
Evidence
- ECO:0000269 PubMed:21441910 ↗
- ECO:0000269 PubMed:29433126 ↗
Complete source annotation
{
"commentType": "CATALYTIC ACTIVITY",
"reaction": {
"name": "L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+)",
"reactionCrossReferences": [
{
"database": "Rhea",
"id": "RHEA:17989"
},
{
"database": "Rhea",
"id": "RHEA-COMP:9863"
},
{
"database": "Rhea",
"id": "RHEA-COMP:11604"
},
{
"database": "ChEBI",
"id": "CHEBI:15378"
},
{
"database": "ChEBI",
"id": "CHEBI:29999"
},
{
"database": "ChEBI",
"id": "CHEBI:30616"
},
{
"database": "ChEBI",
"id": "CHEBI:83421"
},
{
"database": "ChEBI",
"id": "CHEBI:456216"
}
],
"ecNumber": "2.7.11.1",
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21441910"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "29433126"
}
]
}
}L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+)
Evidence
- ECO:0000269 PubMed:21441910 ↗
Complete source annotation
{
"commentType": "CATALYTIC ACTIVITY",
"reaction": {
"name": "L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+)",
"reactionCrossReferences": [
{
"database": "Rhea",
"id": "RHEA:46608"
},
{
"database": "Rhea",
"id": "RHEA-COMP:11060"
},
{
"database": "Rhea",
"id": "RHEA-COMP:11605"
},
{
"database": "ChEBI",
"id": "CHEBI:15378"
},
{
"database": "ChEBI",
"id": "CHEBI:30013"
},
{
"database": "ChEBI",
"id": "CHEBI:30616"
},
{
"database": "ChEBI",
"id": "CHEBI:61977"
},
{
"database": "ChEBI",
"id": "CHEBI:456216"
}
],
"ecNumber": "2.7.11.1",
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21441910"
}
]
}
}Cofactors
Zn(2+) · CHEBI:29105
Evidence
- ECO:0000250
Binds 2 Zn(2+) ions per subunit.
Evidence & references
- ECO:0000250
Complete source annotation
{
"commentType": "COFACTOR",
"cofactors": [
{
"name": "Zn(2+)",
"evidences": [
{
"evidenceCode": "ECO:0000250"
}
],
"cofactorCrossReference": {
"database": "ChEBI",
"id": "CHEBI:29105"
}
}
],
"note": {
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250"
}
],
"value": "Binds 2 Zn(2+) ions per subunit."
}
]
}
}Activity regulation
In quiescent cells, maintained in an inactive state via an intramolecular interaction between the protein kinase and N-terminal domains. Following mitogen-mediated cell activation, binds via its RGB domain to active HRAS (GTP-bound) which releases the inhibitory intramolecular interaction between the two domains. This allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which activates BRAF
Evidence & references
- ECO:0000269 PubMed:29433126 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "29433126"
}
],
"value": "In quiescent cells, maintained in an inactive state via an intramolecular interaction between the protein kinase and N-terminal domains. Following mitogen-mediated cell activation, binds via its RGB domain to active HRAS (GTP-bound) which releases the inhibitory intramolecular interaction between the two domains. This allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which activates BRAF"
}
],
"commentType": "ACTIVITY REGULATION"
}GO functions & biological processes
GO:0031267 · evidence & context
- ECO:0000353 PMID:12194967 ↗ IPI · UniProt · 20131211qualifier: NOT|enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O95057"}]}]
GO:0004672 · evidence & context
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28028"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000002487"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001245"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR008271"}]}]
- ECO:0000314 PMID:17563371 ↗ IDA · BHF-UCL · 20120621qualifier: enables
- ECO:0000304 PMID:2284096 ↗ TAS · PINC · 20030904qualifier: enables
GO:0004674 · evidence & context
- ECO:0000501 GO_REF:0000003 IEA · UniProt · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "EC", "id": "2.7.11.1"}]}]
- ECO:0000314 PMID:19667065 ↗ IDA · UniProt · 20110318qualifier: enables
GO:0004674 · evidence & context
- ECO:0000314 PMID:18567582 ↗ IDA · BHF-UCL · 20200117qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750", "relation": "has_input"}, {"db": "GO", "id": "0007173", "relation": "part_of"}]}]
GO:0004708 · evidence & context
- ECO:0000315 PMID:29433126 ↗ IMP · UniProt · 20210525qualifier: enables
All recorded function and process assertions (27)
GO:0004709 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20241121qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0003079"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:97847"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN001147804"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2148"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3531"}]}, {"connectedXrefs": [{"db": "RGD", "id": "619908"}]}]
GO:0005509 · evidence & context
- ECO:0000314 PMID:18567582 ↗ IDA · BHF-UCL · 20200117qualifier: enables
GO:0005515 · evidence & context
- ECO:0000353 PMID:12620389 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31946"}]}]
- ECO:0000353 PMID:15161933 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:15778465 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31947"}]}]
- ECO:0000353 PMID:16810323 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02156"}]}]
- ECO:0000353 PMID:16810323 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q13233"}]}]
- ECO:0000353 PMID:16810323 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q15349"}]}]
- ECO:0000353 PMID:16888650 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q13233"}]}]
- ECO:0000353 PMID:17380122 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8CGE9"}]}]
- ECO:0000353 PMID:17563371 ↗ IPI · BHF-UCL · 20120621qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P46940"}]}]
- ECO:0000353 PMID:17563371 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P46940"}]}]
- ECO:0000353 PMID:17979178 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P08238"}]}]
- ECO:0000353 PMID:17979178 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10398"}]}]
- ECO:0000353 PMID:17979178 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}]
- ECO:0000353 PMID:17979178 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P62258"}]}]
- ECO:0000353 PMID:17979178 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:18567582 ↗ IPI · BHF-UCL · 20200117qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P46940"}]}]
- ECO:0000353 PMID:20130576 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10398"}]}]
- ECO:0000353 PMID:21441910 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P29678"}]}]
- ECO:0000353 PMID:21478863 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01111"}]}]
- ECO:0000353 PMID:21625473 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02156"}]}]
- ECO:0000353 PMID:22510884 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q61097"}]}]
- ECO:0000353 PMID:22510884 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99N57"}]}]
- ECO:0000353 PMID:22939624 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P08238"}]}]
- ECO:0000353 PMID:23153539 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q13114"}]}]
- ECO:0000353 PMID:24255178 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31946"}]}]
- ECO:0000353 PMID:24441586 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01112"}]}]
- ECO:0000353 PMID:24746704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}]
- ECO:0000353 PMID:25241761 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10398"}]}]
- ECO:0000353 PMID:25241761 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31749"}]}]
- ECO:0000353 PMID:25600339 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}]
- ECO:0000353 PMID:26165597 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01112"}]}]
- ECO:0000353 PMID:26496610 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:27353360 ↗ IPI · UniProt · 20161004qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8TF40"}]}]
- ECO:0000353 PMID:27353360 ↗ IPI · UniProt · 20161004qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9P278"}]}]
- ECO:0000353 PMID:28514442 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01112"}]}]
- ECO:0000353 PMID:28514442 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10398"}]}]
- ECO:0000353 PMID:28514442 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}]
- ECO:0000353 PMID:28514442 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P62258"}]}]
- ECO:0000353 PMID:28514442 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:28514442 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8N122"}]}]
- ECO:0000353 PMID:29433126 ↗ IPI · UniProt · 20190709qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q6VAB6"}]}]
- ECO:0000353 PMID:29433126 ↗ IPI · UniProt · 20190709qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8IVT5"}]}]
- ECO:0000353 PMID:30194290 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01111"}]}]
- ECO:0000353 PMID:30194290 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01112"}]}]
- ECO:0000353 PMID:31024343 ↗ IPI · UniProt · 20190927qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P08238"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10398"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31946"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31947"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P62258"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8N122"}]}]
- ECO:0000353 PMID:32707033 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01111"}]}]
- ECO:0000353 PMID:32707033 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31946"}]}]
- ECO:0000353 PMID:32707033 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}]
- ECO:0000353 PMID:32707033 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P62258"}]}]
- ECO:0000353 PMID:32707033 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01112"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10398"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31946"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P62258"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:34591642 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01111"}]}]
- ECO:0000353 PMID:34591642 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01112"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O00255"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O14920"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O14965"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O15297"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O43524"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O75874"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01111"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01112"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04637"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P07196"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P08238"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10398"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P16885"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P17174"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P18074"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P21399"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P25311"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P27986"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P27987"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28715"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31749"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31946"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31947"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P35221"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P36507"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P40259"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P40337"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P42772"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P48736"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P49407"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P49840"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P57735"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P61024"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P61224"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P62258"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q07817"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q07864"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q12967"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q13164"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q13618"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q15759"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q16254"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q16659"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q6P1J9"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q7Z589"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8IYM1"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8N122"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8WXI9"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q92560"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q92843"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9BRP1"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9GZV4"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NX70"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9UMX1"}]}]
- ECO:0000353 PMID:35839996 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01112"}]}]
- ECO:0000353 PMID:36241744 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O95714"}]}]
- ECO:0000353 PMID:36931259 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31946"}]}]
- ECO:0000353 PMID:36931259 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31947"}]}]
- ECO:0000353 PMID:36931259 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P62258"}]}]
- ECO:0000353 PMID:36931259 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P63104"}]}]
- ECO:0000353 PMID:40205054 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31946"}]}]
GO:0005515 · evidence & context
- ECO:0000353 PMID:17979178 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:20130576 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:20141835 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:22169110 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:22510884 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:23680146 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:23934108 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:23934108 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:24746704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:25155755 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:25155755 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:25437913 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:25600339 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:26466569 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:26496610 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:32707033 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q02750"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:37045861 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
GO:0005515 · evidence & context
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14145"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005737", "relation": "occurs_in"}]}]
GO:0005524 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR000719"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR017441"}]}]
GO:0042802 · evidence & context
- ECO:0000353 PMID:16858395 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:19727074 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:22169110 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:22510884 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:25155755 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:25437913 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:35512704 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005829", "relation": "occurs_in"}]}]
GO:0097110 · evidence & context
- ECO:0000353 PMID:18567582 ↗ IPI · BHF-UCL · 20200117qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P46940"}]}]
GO:0106310 · evidence & context
- ECO:0007322 GO_REF:0000116 IEA · RHEA · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "RHEA", "id": "17989"}]}]
- ECO:0000269 PMID:21441910 ↗ EXP · UniProt · 20251027qualifier: enables
- ECO:0000269 PMID:29433126 ↗ EXP · UniProt · 20251027qualifier: enables
GO:0000165 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250904qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0003079"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:97847"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN001147804"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3531"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}, {"connectedXrefs": [{"db": "WB", "id": "WBGene00003030"}]}]
- ECO:0000314 PMID:18567582 ↗ IDA · BHF-UCL · 20200117qualifier: involved_in
- ECO:0000314 PMID:29433126 ↗ IDA · UniProt · 20210525qualifier: involved_in
GO:0006468 · evidence & context
- ECO:0000304 PMID:2284096 ↗ TAS · PINC · 20030904qualifier: involved_in
GO:0007165 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR003116"}]}]
GO:0007173 · evidence & context
- ECO:0000314 PMID:18567582 ↗ IDA · BHF-UCL · 20200117qualifier: involved_in
GO:0009887 · evidence & context
- ECO:0000304 PMID:9207797 ↗ TAS · PINC · 20031120qualifier: involved_in
GO:0010628 · evidence & context
- ECO:0000315 PMID:22065586 ↗ IMP · BHF-UCL · 20111212qualifier: involved_in
GO:0010828 · evidence & context
- ECO:0000314 PMID:23010278 ↗ IDA · CACAO · 20121002qualifier: involved_in
GO:0033138 · evidence & context
- ECO:0000314 PMID:19667065 ↗ IDA · UniProt · 20110318qualifier: involved_in
GO:0043066 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00027746"}]}]
- ECO:0000314 PMID:19667065 ↗ IDA · UniProt · 20110318qualifier: involved_in
- ECO:0000304 PMID:9207797 ↗ TAS · PINC · 20030904qualifier: involved_in
GO:0070374 · evidence & context
- ECO:0000314 PMID:22065586 ↗ IDA · BHF-UCL · 20111212qualifier: involved_in
GO:0071277 · evidence & context
- ECO:0000314 PMID:18567582 ↗ IDA · BHF-UCL · 20151110qualifier: involved_in
GO:0090150 · evidence & context
- ECO:0000314 PMID:23010278 ↗ IDA · CACAO · 20121016qualifier: involved_in
GO:0099170 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28028"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000002487"}]}]
Names & Taxonomy
- Recommended name
- Serine/threonine-protein kinase B-raf
- Gene
- BRAF
- Accession / entry
- P15056 · BRAF_HUMAN
- Species
- Homo sapiens · NCBI 9606
- Recorded aliases
- BRAF1 · Proto-oncogene B-Raf · RAFB1 · p94 · v-Raf murine sarcoma viral oncogene homolog B1
Full taxonomy & recorded names
Eukaryota → Metazoa → Chordata → Craniata → Vertebrata → Euteleostomi → Mammalia → Eutheria → Euarchontoglires → Primates → Haplorrhini → Catarrhini → Hominidae → Homo
{
"names": {
"recommendedName": {
"fullName": {
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Serine/threonine-protein kinase B-raf"
},
"ecNumbers": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21441910"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "29433126"
}
],
"value": "2.7.11.1"
}
]
},
"alternativeNames": [
{
"fullName": {
"value": "Proto-oncogene B-Raf"
}
},
{
"fullName": {
"value": "p94"
}
},
{
"fullName": {
"value": "v-Raf murine sarcoma viral oncogene homolog B1"
}
}
]
},
"genes": [
{
"geneName": {
"evidences": [
{
"evidenceCode": "ECO:0000312",
"source": "HGNC",
"id": "HGNC:1097"
}
],
"value": "BRAF"
},
"synonyms": [
{
"value": "BRAF1"
},
{
"value": "RAFB1"
}
]
}
]
}Subcellular Location
UniProt locations and GO cellular-component assertions. Relations and contexts remain distinct; “part of” is not automatically a residence claim.
Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes
Evidence & references
- ECO:0000250
Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes
Evidence & references
- ECO:0000269 PubMed:19710016 ↗
Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes
Evidence & references
- ECO:0000269 PubMed:19710016 ↗
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260530qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0030018"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:108212"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346881"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:2443258"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88065"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88190"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002892787"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3531"}]}, {"connectedXrefs": [{"db": "RGD", "id": "620063"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O43353"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q02779"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q13418"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q13546"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q16584"}]}, {"connectedXrefs": [{"db": "WB", "id": "WBGene00003931"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-040426-1435"}]}, {"connectedXrefs": [{"db": "dictyBase", "id": "DDB_G0281557"}]}, {"connectedXrefs": [{"db": "dictyBase", "id": "DDB_G0289555"}]}]
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20170228qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:88065"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88190"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN000584576"}]}]
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20230604qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN000584576"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P04049"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20251220qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:88190"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002892792"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P15056"}]}]
Evidence & references
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28028"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000002487"}]}]
All recorded location assertions (16)
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0191"}]}]
Evidence & references
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28028"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000002487"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0086"}]}]
- ECO:0000269 PMID:19710016 ↗ EXP · UniProt · 20251027qualifier: located_in
Evidence & references
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28028"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000002487"}]}]
Evidence & references
- ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115qualifier: located_in
- ECO:0000304 Reactome:R-HSA-1295604 TAS · Reactome · 20130503qualifier: located_in
- ECO:0000304 Reactome:R-HSA-1295634 TAS · Reactome · 20130503qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672950 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672951 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672960 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672961 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672966 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672969 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672972 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672973 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672978 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5672980 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5674130 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5674132 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5674140 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5675417 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5675431 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5675433 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802910 TAS · Reactome · 20230401qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802911 TAS · Reactome · 20230401qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802912 TAS · Reactome · 20230401qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802914 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802915 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802916 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802918 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802919 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802921 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802924 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802930 TAS · Reactome · 20230401qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802937 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802938 TAS · Reactome · 20230401qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802941 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802942 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802943 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6803227 TAS · Reactome · 20230401qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6803230 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6803234 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6803240 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-8936676 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-8936731 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9610152 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9610153 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9610154 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9610156 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9610163 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9653108 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9656209 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9656211 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9656212 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9656213 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9656214 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9656215 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9657599 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9657603 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9657606 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9657608 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9658445 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9660536 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9660538 TAS · Reactome · 20230428qualifier: located_in
Evidence & references
- ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115qualifier: located_in
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28028"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000002487"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0039"}]}]
- ECO:0000269 PMID:19710016 ↗ EXP · UniProt · 20251027qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5675198 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802908 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802914 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802916 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802919 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802921 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802922 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802924 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802925 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6802926 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6803230 TAS · Reactome · 20190625qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6803233 TAS · Reactome · 20230428qualifier: located_in
- ECO:0000304 Reactome:R-HSA-6803240 TAS · Reactome · 20230428qualifier: located_in
Evidence & references
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28028"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000002487"}]}]
Evidence & references
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28028"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000002487"}]}]
Evidence & references
- ECO:0000366 GO_REF:0000108 IEA · GOC · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "GO", "id": "0099170"}]}]
Membrane topology 0
No annotation is recorded in this UniProt entry.
Disease & Variants
Source annotations; a recorded variant is not automatically a clinical classification.
Defects in BRAF are found in a wide range of cancers
Evidence & references
- ECO:0000269 PubMed:18974108 ↗
Complete source annotation
{
"commentType": "DISEASE",
"note": {
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18974108"
}
],
"value": "Defects in BRAF are found in a wide range of cancers"
}
]
}
}Colorectal cancer CRC
A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.
Evidence & references
- ECO:0000269 PubMed:12198537 ↗
- ECO:0000269 PubMed:21917714 ↗
- ECO:0000269 PubMed:23263490 ↗
- ECO:0000269 PubMed:24455489 ↗
The disease may be caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Colorectal cancer",
"diseaseAccession": "DI-01359",
"acronym": "CRC",
"description": "A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.",
"diseaseCrossReference": {
"database": "MIM",
"id": "114500"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12198537"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21917714"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23263490"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24455489"
}
]
},
"note": {
"texts": [
{
"value": "The disease may be caused by variants affecting the gene represented in this entry"
}
]
}
}Lung cancer LNCR
A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
Evidence & references
- ECO:0000269 PubMed:12460919 ↗
The gene represented in this entry is involved in disease pathogenesis
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Lung cancer",
"diseaseAccession": "DI-02205",
"acronym": "LNCR",
"description": "A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.",
"diseaseCrossReference": {
"database": "MIM",
"id": "211980"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12460919"
}
]
},
"note": {
"texts": [
{
"value": "The gene represented in this entry is involved in disease pathogenesis"
}
]
}
}Familial non-Hodgkin lymphoma NHL
Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.
Evidence & references
- ECO:0000269 PubMed:14612909 ↗
The gene represented in this entry is involved in disease pathogenesis
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Familial non-Hodgkin lymphoma",
"diseaseAccession": "DI-01594",
"acronym": "NHL",
"description": "Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.",
"diseaseCrossReference": {
"database": "MIM",
"id": "605027"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "14612909"
}
]
},
"note": {
"texts": [
{
"value": "The gene represented in this entry is involved in disease pathogenesis"
}
]
}
}Cardiofaciocutaneous syndrome 1 CFC1
A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and intellectual disability. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices.
Evidence & references
- ECO:0000269 PubMed:16439621 ↗
- ECO:0000269 PubMed:16474404 ↗
- ECO:0000269 PubMed:18042262 ↗
- ECO:0000269 PubMed:19206169 ↗
The disease is caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Cardiofaciocutaneous syndrome 1",
"diseaseAccession": "DI-01318",
"acronym": "CFC1",
"description": "A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and intellectual disability. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices.",
"diseaseCrossReference": {
"database": "MIM",
"id": "115150"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16439621"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16474404"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18042262"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19206169"
}
]
},
"note": {
"texts": [
{
"value": "The disease is caused by variants affecting the gene represented in this entry"
}
]
}
}Noonan syndrome 7 NS7
A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells.
Evidence & references
- ECO:0000269 PubMed:19206169 ↗
The disease is caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Noonan syndrome 7",
"diseaseAccession": "DI-02990",
"acronym": "NS7",
"description": "A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells.",
"diseaseCrossReference": {
"database": "MIM",
"id": "613706"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19206169"
}
]
},
"note": {
"texts": [
{
"value": "The disease is caused by variants affecting the gene represented in this entry"
}
]
}
}LEOPARD syndrome 3 LPRD3
A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
Evidence & references
- ECO:0000269 PubMed:19206169 ↗
The disease is caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "LEOPARD syndrome 3",
"diseaseAccession": "DI-02991",
"acronym": "LPRD3",
"description": "A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.",
"diseaseCrossReference": {
"database": "MIM",
"id": "613707"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19206169"
}
]
},
"note": {
"texts": [
{
"value": "The disease is caused by variants affecting the gene represented in this entry"
}
]
}
}A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation
Evidence & references
- ECO:0000269 PubMed:18974108 ↗
Complete source annotation
{
"commentType": "DISEASE",
"note": {
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18974108"
}
],
"value": "A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation"
}
]
}
}Natural variants 47
Scroll across the table for evidence and actions.
47 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| T241MVAR_058620 | 241 | in NS7; dbSNP:rs387906660 T → M | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T241PVAR_058621 | 241 | in CFC1 and LPRD3; dbSNP:rs387906661 T → P | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| T241RVAR_058622 | 241 | in NS7; dbSNP:rs387906660 T → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T244PVAR_065171 | 244 | in CFC1; dbSNP:rs397507465 T → P | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L245FVAR_058623 | 245 | in CFC1; dbSNP:rs397507466 L → F | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| A246PVAR_026113 | 246 | in CFC1; dbSNP:rs180177034 A → P | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| Q257RVAR_026114 | 257 | in CFC1; dbSNP:rs180177035 Q → R | Experimental evidence 4 publications Evidence & references
| No verified residues in this structure |
| Q262KVAR_065172 | 262 | in CFC1; dbSNP:rs397507470 Q → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E275KVAR_058624 | 275 | in CFC1; dbSNP:rs2129044284 E → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P301SVAR_040391 | 301 | in dbSNP:rs34776339 P → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R462IVAR_018613 | 462 | in CRC; dbSNP:rs180177032 R → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| I463SVAR_018614 | 463 | in CRC; dbSNP:rs180177033 I → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G464EVAR_018615 | 464 | in CRC; dbSNP:rs121913348 G → E | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| G464VVAR_018616 | 464 | in a colorectal cancer cell line; elevated kinase activity; efficiently induces cell transformation; dbSNP:rs121913348 G → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G466AVAR_018617 | 466 | in melanoma; dbSNP:rs121913351 G → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G466EVAR_018618 | 466 | in melanoma; dbSNP:rs121913351 G → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G466VVAR_018512 | 466 | in LNCR; dbSNP:rs121913351 G → V | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| S467AVAR_035096 | 467 | in CFC1; dbSNP:rs869025606 S → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F468SVAR_035097 | 468 | in CFC1; dbSNP:rs397507473 F → S | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| G469AVAR_018620 | 469 | in NHL; also in a lung adenocarcinoma sample; somatic mutation; elevated kinase activity; efficiently induces cell transformation; dbSNP:rs121913355 G → A | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| G469EVAR_018621 | 469 | in CFC1 and colon cancer; dbSNP:rs121913355 G → E | Experimental evidence 5 publications Evidence & references
| No verified residues in this structure |
| G469RVAR_018622 | 469 | in NHL; dbSNP:rs121913357 G → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G469VVAR_040392 | 469 | in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913355 G → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L485FVAR_026115 | 485 | in CFC1; dbSNP:rs180177036 L → F | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| K499EVAR_026116 | 499 | in CFC1; dbSNP:rs180177037 K → E | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| K499NVAR_058625 | 499 | in CFC1; dbSNP:rs397507476 K → N | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| E501GVAR_026117 | 501 | in CFC1; dbSNP:rs180177039 E → G | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| E501KVAR_026118 | 501 | in CFC1; dbSNP:rs180177038 E → K | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| L525PVAR_058626 | 525 | in CFC1; dbSNP:rs869025340 L → P | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| W531CVAR_058627 | 531 | in NS7; dbSNP:rs606231228 W → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N580DVAR_065173 | 580 | in CFC1; dbSNP:rs2128999571 N → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N581DVAR_026119 | 581 | in CFC1; dbSNP:rs180177040 N → D | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| N581SVAR_040393 | 581 | in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913370 N → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E586KVAR_018623 | 586 | in ovarian cancer; dbSNP:rs121913340 E → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D594GVAR_018624 | 594 | in NHL; dbSNP:rs121913338 D → G | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F595LVAR_018625 | 595 | in CFC1; also found in colon cancer; dbSNP:rs121913341 F → L | Experimental evidence 4 publications Evidence & references
| No verified residues in this structure |
| G596RVAR_018626 | 596 | in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913361 G → R | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| G596VVAR_035098 | 596 | in CFC1; dbSNP:rs397507483 G → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L597RVAR_018513 | 597 | in LNCR; also found in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs121913366 L → R | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| L597VVAR_018627 | 597 | in NS7; also in a lung adenocarcinoma sample; somatic mutation; elevated kinase activity; efficiently induces cell transformation; dbSNP:rs121913369 L → V | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| T599RVAR_058628 | 599 | in CFC1; dbSNP:rs121913375 T → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V600DVAR_018628 | 600 | in a melanoma cell line; requires 2 nucleotide substitutions; dbSNP:rs121913377 V → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V600EVAR_018629 | 600 | in CRC; also found in sarcoma, metastatic melanoma, ovarian serous carcinoma, pilocytic astrocytoma; somatic mutation; most common mutation; constitutive and elevated kinase activity; efficiently induces cell transformation; suppression of mutation in melanoma causes growth arrest and promotes apoptosis; loss of regulation by PMRT5; dbSNP:rs113488022 V → E | Experimental evidence 8 publications Evidence & references
| No verified residues in this structure |
| K601EVAR_018630 | 601 | in CRC; dbSNP:rs121913364 K → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K601QVAR_058629 | 601 | in CFC1; dbSNP:rs121913364 K → Q | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D638EVAR_058630 | 638 | in CFC1; dbSNP:rs180177042 D → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q709RVAR_058631 | 709 | in CFC1; dbSNP:rs397507486 Q → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Laboratory mutagenesis 7
Scroll across the table for evidence and actions.
7 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| M53D | 53 | Reduces interaction with KSR1 and MAP2K1 and thus phosphorylation of MAP2K1. M → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K88E | 88 | Reduces interaction with KSR1 and MAP2K1 and thus phosphorylation of MAP2K1. K → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K483S | 483 | Reduces kinase activity with MAP2K1. K → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R509H | 509 | Loss of MAP2K1-mediated-BRAF-KSR1 dimerization. R → H | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K578R | 578 | Blocks EGF-induced ubiquitination and ERK activation. K → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| I666R | 666 | No effect on MAP2K1-mediated-BRAF-KSR1 dimerization, however loss of BRAF-mediated phosphorylation of MAP2K1. I → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R671K | 671 | Increased kinase activity and stability in response to EGF treatment. R → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
PTM/Processing
Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 [16]. Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); this relieves inactivation and stimulates kinase activity [30, 31]
Evidence & references
- ECO:0000269 PubMed:11410590 ↗
- ECO:0000269 PubMed:19710016 ↗
- ECO:0000269 PubMed:35768504 ↗
- ECO:0000269 PubMed:35830882 ↗
- ECO:0000269 Reference:Ref.8
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11410590"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19710016"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35768504"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35830882"
},
{
"evidenceCode": "ECO:0000269",
"source": "Reference",
"id": "Ref.8"
}
],
"value": "Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 (PubMed:19710016). Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); this relieves inactivation and stimulates kinase activity (PubMed:35768504, PubMed:35830882)"
}
],
"commentType": "PTM"
}Methylation at Arg-671 decreases stability and kinase activity
Evidence & references
- ECO:0000269 PubMed:21917714 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21917714"
}
],
"value": "Methylation at Arg-671 decreases stability and kinase activity"
}
],
"commentType": "PTM"
}Ubiquitinated by RNF149; which leads to proteasomal degradation. Polyubiquitinated at Lys-578 in response to EGF
Evidence & references
- ECO:0000269 PubMed:22628551 ↗
- ECO:0000269 PubMed:23907581 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22628551"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23907581"
}
],
"value": "Ubiquitinated by RNF149; which leads to proteasomal degradation. Polyubiquitinated at Lys-578 in response to EGF"
}
],
"commentType": "PTM"
}Processed chains & precursor regions 2
Scroll across the table for evidence and actions.
2 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Initiator methionine | 1 | Removed | Experimental evidence Evidence & references
| No verified residues in this structure |
| ChainPRO_0000085665 | 2–766 | Serine/threonine-protein kinase B-raf | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
Modifications 15
Scroll across the table for evidence and actions.
15 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Modified residue | 2 | N-acetylalanine | Experimental evidence Evidence & references
| No verified residues in this structure |
| Modified residue | 151 | Phosphoserine | 2 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 333 | Phosphoserine | By similarity Evidence & references
| No verified residues in this structure |
| Modified residue | 365 | Phosphoserine; by SGK1 | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 373 | Phosphothreonine; by autocatalysis | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 396 | Phosphothreonine | Experimental evidence Evidence & references
| No verified residues in this structure |
| Modified residue | 399 | Phosphoserine | Experimental evidence Evidence & references
| No verified residues in this structure |
| Modified residue | 401 | Phosphothreonine | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 446 | Phosphoserine | 2 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 447 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 671 | Omega-N-methylarginine; by PRMT5 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 729 | Phosphoserine | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 750 | Phosphoserine | By similarity Evidence & references
| No verified residues in this structure |
| Modified residue | 753 | Phosphothreonine; by MAPK1 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Cross-link | 578 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Expression
Brain and testis
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"texts": [
{
"value": "Brain and testis"
}
],
"commentType": "TISSUE SPECIFICITY"
}Interaction
Documented interaction partners
UniProt’s filtered IntAct records. Experiment counts describe reported experiments, not binding strength or independent publications. Separate products remain separate rows.
| Partner / product | Species | Experiments | Evidence & actions |
|---|---|---|---|
| ACO1P21399With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P21399. Reported experiment count: 4. |
| AKT1P31749With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P31749. Reported experiment count: 4. |
| ARAFP10398With P15056 | Homo sapiens | 9 | IntAct evidenceSource product: P15056. Partner: P10398. Reported experiment count: 9. |
| ARRB1P49407With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P49407. Reported experiment count: 4. |
| AURKAO14965With P15056 | Homo sapiens | 5 | IntAct evidenceSource product: P15056. Partner: O14965. Reported experiment count: 5. |
| AZGP1P25311With P15056 | Homo sapiens | 3 | IntAct evidenceSource product: P15056. Partner: P25311. Reported experiment count: 3. |
| BAP1Q92560With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q92560. Reported experiment count: 4. |
| BCL2L1Q07817With P15056 | Homo sapiens | 7 | IntAct evidenceSource product: P15056. Partner: Q07817. Reported experiment count: 7. |
| BCL2L2Q92843With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q92843. Reported experiment count: 4. |
| BRAFP15056With P15056 | Homo sapiens | 14 | IntAct evidenceSource product: P15056. Partner: P15056. Reported experiment count: 14. |
| CD79BP40259With P15056 | Homo sapiens | 3 | IntAct evidenceSource product: P15056. Partner: P40259. Reported experiment count: 3. |
| CDC73Q6P1J9With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q6P1J9. Reported experiment count: 4. |
| CDKN2BP42772With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P42772. Reported experiment count: 4. |
| CKS1BP61024With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P61024. Reported experiment count: 4. |
| CTNNA1P35221With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P35221. Reported experiment count: 4. |
| CUL3Q13618With P15056 | Homo sapiens | 2 | IntAct evidenceSource product: P15056. Partner: Q13618. Reported experiment count: 2. |
| E2F4Q16254With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q16254. Reported experiment count: 4. |
| EIF5A2Q9GZV4With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q9GZV4. Reported experiment count: 4. |
| EMSYQ7Z589With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q7Z589. Reported experiment count: 4. |
| ERCC2P18074With P15056 | Homo sapiens | 3 | IntAct evidenceSource product: P15056. Partner: P18074. Reported experiment count: 3. |
| ERCC5P28715With P15056 | Homo sapiens | 3 | IntAct evidenceSource product: P15056. Partner: P28715. Reported experiment count: 3. |
| FOXO3O43524With P15056 | Homo sapiens | 5 | IntAct evidenceSource product: P15056. Partner: O43524. Reported experiment count: 5. |
| GATAD2BQ8WXI9With P15056 | Homo sapiens | 3 | IntAct evidenceSource product: P15056. Partner: Q8WXI9. Reported experiment count: 3. |
| GOT1P17174With P15056 | Homo sapiens | 5 | IntAct evidenceSource product: P15056. Partner: P17174. Reported experiment count: 5. |
| GSK3AP49840With P15056 | Homo sapiens | 6 | IntAct evidenceSource product: P15056. Partner: P49840. Reported experiment count: 6. |
| HERC2O95714With P15056 | Homo sapiens | 2 | IntAct evidenceSource product: P15056. Partner: O95714. Reported experiment count: 2. |
| HRASP01112With P15056 | Homo sapiens | 10 | IntAct evidenceSource product: P15056. Partner: P01112. Reported experiment count: 10. |
| HSP90AB1P08238With P15056 | Homo sapiens | 5 | IntAct evidenceSource product: P15056. Partner: P08238. Reported experiment count: 5. |
| IDH1O75874With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: O75874. Reported experiment count: 4. |
| IKBKBO14920With P15056 | Homo sapiens | 5 | IntAct evidenceSource product: P15056. Partner: O14920. Reported experiment count: 5. |
| IQGAP1P46940With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P46940. Reported experiment count: 4. |
| ITPKBP27987With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P27987. Reported experiment count: 4. |
| KEAP1Q14145With P15056 | Homo sapiens | 16 | IntAct evidenceSource product: P15056. Partner: Q14145. Reported experiment count: 16. |
| MAP2K1Q02750With P15056 | Homo sapiens | 65 | IntAct evidenceSource product: P15056. Partner: Q02750. Reported experiment count: 65. |
| MAP2K2P36507With P15056 | Homo sapiens | 13 | IntAct evidenceSource product: P15056. Partner: P36507. Reported experiment count: 13. |
| MAP3K1Q13233With P15056 | Homo sapiens | 2 | IntAct evidenceSource product: P15056. Partner: Q13233. Reported experiment count: 2. |
| MAPK11Q15759With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q15759. Reported experiment count: 4. |
| MAPK6Q16659With P15056 | Homo sapiens | 3 | IntAct evidenceSource product: P15056. Partner: Q16659. Reported experiment count: 3. |
| MAPK7Q13164With P15056 | Homo sapiens | 5 | IntAct evidenceSource product: P15056. Partner: Q13164. Reported experiment count: 5. |
| MED29Q9NX70With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q9NX70. Reported experiment count: 4. |
| MEN1O00255With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: O00255. Reported experiment count: 4. |
| NEFLP07196With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P07196. Reported experiment count: 4. |
| NRASP01111With P15056 | Homo sapiens | 8 | IntAct evidenceSource product: P15056. Partner: P01111. Reported experiment count: 8. |
| PDCD2LQ9BRP1With P15056 | Homo sapiens | 6 | IntAct evidenceSource product: P15056. Partner: Q9BRP1. Reported experiment count: 6. |
| PIK3CGP48736With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P48736. Reported experiment count: 4. |
| PIK3R1P27986With P15056 | Homo sapiens | 3 | IntAct evidenceSource product: P15056. Partner: P27986. Reported experiment count: 3. |
| PLCG2P16885With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P16885. Reported experiment count: 4. |
| POLEQ07864With P15056 | Homo sapiens | 6 | IntAct evidenceSource product: P15056. Partner: Q07864. Reported experiment count: 6. |
| PPM1DO15297With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: O15297. Reported experiment count: 4. |
| PRKCEQ02156With P15056 | Homo sapiens | 3 | IntAct evidenceSource product: P15056. Partner: Q02156. Reported experiment count: 3. |
| RAB25P57735With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P57735. Reported experiment count: 4. |
| RAF1P04049With P15056 | Homo sapiens | 73 | IntAct evidenceSource product: P15056. Partner: P04049. Reported experiment count: 73. |
| RALGDSQ12967With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q12967. Reported experiment count: 4. |
| RAP1BP61224With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P61224. Reported experiment count: 4. |
| RPS6KA2Q15349With P15056 | Homo sapiens | 2 | IntAct evidenceSource product: P15056. Partner: Q15349. Reported experiment count: 2. |
| RPTORQ8N122With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q8N122. Reported experiment count: 4. |
| SEPTIN12Q8IYM1With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q8IYM1. Reported experiment count: 4. |
| SFNP31947With P15056 | Homo sapiens | 6 | IntAct evidenceSource product: P15056. Partner: P31947. Reported experiment count: 6. |
| SUFUQ9UMX1With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: Q9UMX1. Reported experiment count: 4. |
| TP53P04637With P15056 | Homo sapiens | 4 | IntAct evidenceSource product: P15056. Partner: P04637. Reported experiment count: 4. |
| TRAF3Q13114With P15056 | Homo sapiens | 2 | IntAct evidenceSource product: P15056. Partner: Q13114. Reported experiment count: 2. |
| VHLP40337With P15056 | Homo sapiens | 7 | IntAct evidenceSource product: P15056. Partner: P40337. Reported experiment count: 7. |
| YWHABP31946With P15056 | Homo sapiens | 12 | IntAct evidenceSource product: P15056. Partner: P31946. Reported experiment count: 12. |
| YWHAEP62258With P15056 | Homo sapiens | 11 | IntAct evidenceSource product: P15056. Partner: P62258. Reported experiment count: 11. |
| YWHAZP63104With P15056 | Homo sapiens | 13 | IntAct evidenceSource product: P15056. Partner: P63104. Reported experiment count: 13. |
| Ksr1Q61097With P15056 | Mus musculusCross-species | 3 | IntAct evidenceSource product: P15056. Partner: Q61097. Reported experiment count: 3. |
| MAP2K1P29678With P15056 | Oryctolagus cuniculusCross-species | 2 | IntAct evidenceSource product: P15056. Partner: P29678. Reported experiment count: 2. |
| Raf1Q99N57With P15056 | Mus musculusCross-species | 3 | IntAct evidenceSource product: P15056. Partner: Q99N57. Reported experiment count: 3. |
| Rgs12Q8CGE9With P15056 | Mus musculusCross-species | 2 | IntAct evidenceSource product: P15056. Partner: Q8CGE9. Reported experiment count: 2. |
No partners match this filter.
Complex membership & assembly descriptions
Co-membership does not by itself prove direct binding between every pair.
No Complex Portal cross-reference was recorded for this entry.
UniProt subunit description
Monomer [16]. Homodimer [16, 29]. Heterodimerizes with RAF1, and the heterodimer possesses a highly increased kinase activity compared to the respective homodimers or monomers [16].
Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 activation can induce a negative feedback that promotes the dissociation of the heterodimer by phosphorylating BRAF at Thr-753. Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 (via N-terminus) in a MAP2K1-dependent manner [33].
Interacts with MAP2K1 and MAP2K2 [33]. Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1.
Interacts (via N-terminus) with RGS14 (via RBD domains); the interaction mediates the formation of a ternary complex with RAF1, a ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH [16]. Interacts with PRMT5 [21].
Interacts with KSR2 [20]. Interacts with AKAP13, MAP2K1 and KSR1. Identified in a complex with AKAP13, MAP2K1 and KSR1 [18].
Interacts with FNIP1 and FNIP2 [27]
Evidence & references
- ECO:0000250
- ECO:0000269 PubMed:18287029 ↗
- ECO:0000269 PubMed:19710016 ↗
- ECO:0000269 PubMed:21102438 ↗
- ECO:0000269 PubMed:21441910 ↗
- ECO:0000269 PubMed:21917714 ↗
- ECO:0000269 PubMed:27353360 ↗
- ECO:0000269 PubMed:29433126 ↗
- ECO:0000269 PubMed:36402789 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18287029"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19710016"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21102438"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21441910"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21917714"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27353360"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "29433126"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "36402789"
}
],
"value": "Monomer (PubMed:19710016). Homodimer (PubMed:19710016, PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer possesses a highly increased kinase activity compared to the respective homodimers or monomers (PubMed:19710016). Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 activation can induce a negative feedback that promotes the dissociation of the heterodimer by phosphorylating BRAF at Thr-753. Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126). Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the interaction mediates the formation of a ternary complex with RAF1, a ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714). Interacts with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438). Interacts with FNIP1 and FNIP2 (PubMed:27353360)"
}
],
"commentType": "SUBUNIT"
}Other association resources
Resource links only; their association networks and counts are not added to the partner table.
Structure
8VYS · Cryo-EM Structure of the BRAF V600E monomer bound to PLX8394
ELECTRON MICROSCOPY · 3.06 Å
Recorded components
| Component | Species | Chains | Protein identities |
|---|---|---|---|
| Serine/threonine-protein kinase B-rafprotein · Entity 1 | Homo sapiens | A | P15056 |
| 14-3-3 protein zeta/deltaprotein · Entity 2 | Homo sapiens | B, C | P63104 |
| (3S)-N-{3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}-3-fluoropyrrolidine-1-sulfonamideligand · Entity 3 | D | No verified protein mapping |
Biological assemblies
Assembly 1 · author_defined_assembly
Recorded chains: A, B, C, D
Assembly membership does not establish direct binding. Observed residue coverage is checked against the loaded coordinates; it is not inferred from construct metadata.
Publication
BRAF oncogenic mutants evade autoinhibition through a common mechanism.
29/05/2025 · Read publication ↗
Detailed validation, construct lengths and deposition dates are not included in this published record. See the source record for those details.
PDB source record ↗Structure references are from the dated source record. Opening another structure follows your existing Atlas account permissions.
Available structures 132
Scroll across the table for evidence and actions.
132 recorded rows
| Record | Evidence type | Method | Resolution | Open |
|---|---|---|---|---|
| 8VYS | experimental | EM | 3.06 A | Open in Atlas ↗ |
| 8VYP | experimental | EM | 3.29 A | Open in Atlas ↗ |
| 7ZR0 | experimental | EM | 3.40 A | Open in Atlas ↗ |
| 7MFD | experimental | EM | 3.66 A | Open in Atlas ↗ |
| 8VYO | experimental | EM | 3.74 A | Open in Atlas ↗ |
| 9O2Z | experimental | EM | 3.83 A | Open in Atlas ↗ |
| 7MFF | experimental | EM | 3.89 A | Open in Atlas ↗ |
| 6UAN | experimental | EM | 3.90 A | Open in Atlas ↗ |
| 7ZR5 | experimental | EM | 3.90 A | Open in Atlas ↗ |
| 8DGT | experimental | EM | 3.90 A | Open in Atlas ↗ |
| 7MFE | experimental | EM | 4.07 A | Open in Atlas ↗ |
| 8VYU | experimental | EM | 4.07 A | Open in Atlas ↗ |
| 6NYB | experimental | EM | 4.10 A | Open in Atlas ↗ |
| 7ZR6 | experimental | EM | 4.20 A | Open in Atlas ↗ |
| 8DGS | experimental | EM | 4.30 A | Open in Atlas ↗ |
| 8VYR | experimental | EM | 4.32 A | Open in Atlas ↗ |
| 6Q0J | experimental | EM | 4.90 A | Open in Atlas ↗ |
| 6Q0T | experimental | EM | 5.70 A | Open in Atlas ↗ |
| 8VYV | experimental | EM | 5.86 A | Open in Atlas ↗ |
| 6Q0K | experimental | EM | 6.80 A | Open in Atlas ↗ |
| 8C7X | experimental | X-ray | 1.65 A | Open in Atlas ↗ |
| 8C7Y | experimental | X-ray | 1.65 A | Open in Atlas ↗ |
| 9BP8 | experimental | X-ray | 1.73 A | Open in Atlas ↗ |
| 7K0V | experimental | X-ray | 1.93 A | Open in Atlas ↗ |
| 9BFB | experimental | X-ray | 1.92 A | Open in Atlas ↗ |
| 6XFP | experimental | X-ray | 2.00 A | Open in Atlas ↗ |
| 8VYQ | experimental | EM | 4.43 A | Open in Atlas ↗ |
| 8VYW | experimental | EM | 4.76 A | Open in Atlas ↗ |
| 5ITA | experimental | X-ray | 1.95 A | Open in Atlas ↗ |
| 6N0Q | experimental | X-ray | 2.04 A | Open in Atlas ↗ |
| 9AXX | experimental | X-ray | 2.07 A | Open in Atlas ↗ |
| 5VAM | experimental | X-ray | 2.10 A | Open in Atlas ↗ |
| 6P3D | experimental | X-ray | 2.11 A | Open in Atlas ↗ |
| 4E26 | experimental | X-ray | 2.55 A | Open in Atlas ↗ |
| 5JSM | experimental | X-ray | 2.19 A | Open in Atlas ↗ |
| 4MNF | experimental | X-ray | 2.80 A | Open in Atlas ↗ |
| 5VAL | experimental | X-ray | 2.26 A | Open in Atlas ↗ |
| 6U2H | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 4XV9 | experimental | X-ray | 2.00 A | Open in Atlas ↗ |
| 5JRQ | experimental | X-ray | 2.29 A | Open in Atlas ↗ |
| 4CQE | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 5C9C | experimental | X-ray | 2.70 A | Open in Atlas ↗ |
| 3IDP | experimental | X-ray | 2.70 A | Open in Atlas ↗ |
| 3II5 | experimental | X-ray | 2.79 A | Open in Atlas ↗ |
| 6XLO | experimental | X-ray | 2.49 A | Open in Atlas ↗ |
| 7M0X | experimental | X-ray | 2.47 A | Open in Atlas ↗ |
| 5HID | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 3D4Q | experimental | X-ray | 2.80 A | Open in Atlas ↗ |
| 5CSX | experimental | X-ray | 2.51 A | Open in Atlas ↗ |
| 5HI2 | experimental | X-ray | 2.51 A | Open in Atlas ↗ |
| 6N0P | experimental | X-ray | 2.37 A | Open in Atlas ↗ |
| 4MNE | experimental | X-ray | 2.85 A | Open in Atlas ↗ |
| 7P3V | experimental | X-ray | 2.37 A | Open in Atlas ↗ |
| 6CAD | experimental | X-ray | 2.55 A | Open in Atlas ↗ |
| 7SHV | experimental | X-ray | 2.88 A | Open in Atlas ↗ |
| 6U2G | experimental | X-ray | 2.89 A | Open in Atlas ↗ |
| 3PRF | experimental | X-ray | 2.90 A | Open in Atlas ↗ |
| 5FD2 | experimental | X-ray | 2.89 A | Open in Atlas ↗ |
| 6PP9 | experimental | X-ray | 2.59 A | Open in Atlas ↗ |
| 3C4C | experimental | X-ray | 2.57 A | Open in Atlas ↗ |
| 3OG7 | experimental | X-ray | 2.45 A | Open in Atlas ↗ |
| 4FK3 | experimental | X-ray | 2.65 A | Open in Atlas ↗ |
| 5CSW | experimental | X-ray | 2.66 A | Open in Atlas ↗ |
| 8F7P | experimental | X-ray | 2.74 A | Open in Atlas ↗ |
| 3PPK | experimental | X-ray | 3.00 A | Open in Atlas ↗ |
| 5HIE | experimental | X-ray | 3.00 A | Open in Atlas ↗ |
| 6B8U | experimental | X-ray | 2.68 A | Open in Atlas ↗ |
| 6P7G | experimental | X-ray | 2.65 A | Open in Atlas ↗ |
| 5JT2 | experimental | X-ray | 2.70 A | Open in Atlas ↗ |
| 4WO5 | experimental | X-ray | 2.83 A | Open in Atlas ↗ |
| 4XV1 | experimental | X-ray | 2.47 A | Open in Atlas ↗ |
| 4XV2 | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 3Q4C | experimental | X-ray | 3.20 A | Open in Atlas ↗ |
| 3SKC | experimental | X-ray | 3.20 A | Open in Atlas ↗ |
| 4G9R | experimental | X-ray | 3.20 A | Open in Atlas ↗ |
| 4KSP | experimental | X-ray | 2.93 A | Open in Atlas ↗ |
| 4FC0 | experimental | X-ray | 2.95 A | Open in Atlas ↗ |
| 2FB8 | experimental | X-ray | 2.90 A | Open in Atlas ↗ |
| 4RZV | experimental | X-ray | 2.99 A | Open in Atlas ↗ |
| 3TV6 | experimental | X-ray | 3.30 A | Open in Atlas ↗ |
| 4EHE | experimental | X-ray | 3.30 A | Open in Atlas ↗ |
| 1UWH | experimental | X-ray | 2.95 A | Open in Atlas ↗ |
| 6NSQ | experimental | X-ray | 3.05 A | Open in Atlas ↗ |
| 3Q96 | experimental | X-ray | 3.10 A | Open in Atlas ↗ |
| 8QQG | experimental | X-ray | 2.98 A | Open in Atlas ↗ |
| 3TV4 | experimental | X-ray | 3.40 A | Open in Atlas ↗ |
| 4PP7 | experimental | X-ray | 3.40 A | Open in Atlas ↗ |
| 4JVG | experimental | X-ray | 3.09 A | Open in Atlas ↗ |
| 3PSB | experimental | X-ray | 3.40 A | Open in Atlas ↗ |
| 4DBN | experimental | X-ray | 3.15 A | Open in Atlas ↗ |
| 7M0U | experimental | X-ray | 3.09 A | Open in Atlas ↗ |
| 7M0W | experimental | X-ray | 3.09 A | Open in Atlas ↗ |
| 6XAG | experimental | X-ray | 3.30 A | Open in Atlas ↗ |
| 6V2W | experimental | X-ray | 3.12 A | Open in Atlas ↗ |
| 7M0Z | experimental | X-ray | 3.12 A | Open in Atlas ↗ |
| 4XV3 | experimental | X-ray | 2.80 A | Open in Atlas ↗ |
| 7M0V | experimental | X-ray | 3.16 A | Open in Atlas ↗ |
| 3PRI | experimental | X-ray | 3.50 A | Open in Atlas ↗ |
| 4EHG | experimental | X-ray | 3.50 A | Open in Atlas ↗ |
| 4G9C | experimental | X-ray | 3.50 A | Open in Atlas ↗ |
| 5CT7 | experimental | X-ray | 3.17 A | Open in Atlas ↗ |
| 4H58 | experimental | X-ray | 3.10 A | Open in Atlas ↗ |
| 7M0T | experimental | X-ray | 3.19 A | Open in Atlas ↗ |
| 4YHT | experimental | X-ray | 3.05 A | Open in Atlas ↗ |
| 4KSQ | experimental | X-ray | 3.30 A | Open in Atlas ↗ |
| 6V34 | experimental | X-ray | 3.15 A | Open in Atlas ↗ |
| 4E4X | experimental | X-ray | 3.60 A | Open in Atlas ↗ |
| 6UUO | experimental | X-ray | 3.29 A | Open in Atlas ↗ |
| 3PSD | experimental | X-ray | 3.60 A | Open in Atlas ↗ |
| 4MBJ | experimental | X-ray | 3.60 A | Open in Atlas ↗ |
| 3PPJ | experimental | X-ray | 3.70 A | Open in Atlas ↗ |
| 4RZW | experimental | X-ray | 3.49 A | Open in Atlas ↗ |
| 7M0Y | experimental | X-ray | 3.45 A | Open in Atlas ↗ |
| 8F7O | experimental | X-ray | 3.54 A | Open in Atlas ↗ |
| 9ECU | experimental | X-ray | 3.46 A | Open in Atlas ↗ |
| 4R5Y | experimental | X-ray | 3.50 A | Open in Atlas ↗ |
| 1UWJ | experimental | X-ray | 3.50 A | Open in Atlas ↗ |
| 9AXY | experimental | X-ray | 3.60 A | Open in Atlas ↗ |
| 6V2U | experimental | X-ray | 3.78 A | Open in Atlas ↗ |
| 5VYK | experimental | X-ray | 1.75 A | Open in Atlas ↗ |
| 3NY5 | experimental | X-ray | 1.99 A | Open in Atlas ↗ |
| 5VR3 | experimental | X-ray | 2.10 A | Open in Atlas ↗ |
| 8VSO | experimental | X-ray | 1.50 A | Open in Atlas ↗ |
| 8JNB | experimental | X-ray | 1.62 A | Open in Atlas ↗ |
| 9EW6 | experimental | X-ray | 1.65 A | Open in Atlas ↗ |
| 8JNA | experimental | X-ray | 1.70 A | Open in Atlas ↗ |
| 9F35 | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 2L05 | experimental | NMR | - | Open in Atlas ↗ |
| 5J17 | experimental | NMR | - | Open in Atlas ↗ |
| 5J18 | experimental | NMR | - | Open in Atlas ↗ |
| 5J2R | experimental | NMR | - | Open in Atlas ↗ |
| AF-P15056-F1 | predicted | AlphaFold | Not applicable | Open in Atlas ↗ |
Family & Domains
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily
Evidence & references
- ECO:0000305
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily"
}
],
"commentType": "SIMILARITY"
}Domain architecture
Canonical coordinates. Overlapping marks share a lane; individual records and evidence are in the tables below. Gaps in coverage are not selectable in 3D. Use the track links and tables for keyboard inspection.
Atlas domains, motifs & repeats 5
Scroll across the table for evidence and actions.
5 recorded rows
| Annotation | Position | Source & interpretation | Inspect |
|---|---|---|---|
| B-Raf kinase N-terminal domainPF31947 | 45–101 | PFAMdomain This entry represents the N-terminal domain of approximately 60 residues found in B-Raf (BRAF) serine/threonine-protein kinase in vertebrates. This domain is located N-terminal to the RBD domain ([pfam:PF02196]), C1 domain ([pfam:PF00130]), and protein kinase domain ([pfam:PF00069]). Full source descriptionThis entry represents the N-terminal domain of approximately 60 residues found in B-Raf (BRAF) serine/threonine-protein kinase in vertebrates. This domain is located N-terminal to the RBD domain ([pfam:PF02196]), C1 domain ([pfam:PF00130]), and protein kinase domain ([pfam:PF00069]). BRAF is a key component of the RAS-RAF-MEK-ERK signaling pathway that regulates cell proliferation and survival. Mutations in BRAF are found in many cancers, particularly melanoma. This domain is composed of an alpha-helical hairpin. | No verified residues in this structure |
| Raf-like Ras-bindingIPR003116 | 155–227 | INTERPROdomain Ras and heterotrimeric G proteins' alpha subunits are signal-transducing GTPases that cycle between inactive GDP-bound and active GTP-bound forms. The activities of these GTPases are regulated in part by GTPase-activating protein (GAPs) that stimulate hydrolysis of GTP, and guanine nucleotide exchange factors (GEFs) that stimulate GDP release. Full source descriptionRas and heterotrimeric G proteins' alpha subunits are signal-transducing GTPases that cycle between inactive GDP-bound and active GTP-bound forms. The activities of these GTPases are regulated in part by GTPase-activating protein (GAPs) that stimulate hydrolysis of GTP, and guanine nucleotide exchange factors (GEFs) that stimulate GDP release. Ras and G alpha GTPases are prolific signalling molecules interacting with a spectrum of effector molecules and acting through more than one signalling pathway. The Ras-binding domain (RBD) is an independent domain of about 75 residues, which is sufficient for GTP-dependent binding of Ras and other G alpha GTPases. The RBD domain can be present singly or in tandem and it can be found associated with many other domains, such as PDZ, RGS, PID, PH, C1, DH, or protein kinase. Structurally, the RBD domain of Raf-1 consists of a five-stranded mixed beta- sheet with an interrupted α-helix and two additional small α-helices. The structure of the RBD domain belongs to the ubiquitin α/β roll superfold and is similar to that of the RA domain despite the lack of significant sequence identity. The major interaction between Ras and Raf-1 RBD domain occurs between two antiparallel β-strands: β2 of Ras and β2 of RBD. This entry represents the entire RBD domain. | No verified residues in this structure |
| Diacylglycerol/phorbol-ester bindingIPR020454 | 232–246, 248–268, 269–281 | INTERPROdomain This entry represents the N-terminal region of PKC, known as C1. It has been shown to bind PE and DAG in a phospholipid and zinc-dependent fashion. Full source descriptionThis entry represents the N-terminal region of PKC, known as C1. It has been shown to bind PE and DAG in a phospholipid and zinc-dependent fashion. The C1 region contains one or two copies (depending on the isozyme of PKC) of a cysteine-rich domain, which is about 50 amino-acid residues long, and which is essential for DAG/PE-binding. The DAG/PE-binding domain binds two zinc ions; the ligands of these metal ions are probably the six cysteines and two histidines that are conserved in this domain. | No verified residues in this structure |
| Protein kinase domainIPR000719 | 457–717 | INTERPROdomain This entry represents the protein kinase domain containing the catalytic function of protein kinases. This domain is found in serine/threonine-protein kinases, tyrosine-protein kinases and dual specificity protein kinases. Full source descriptionThis entry represents the protein kinase domain containing the catalytic function of protein kinases. This domain is found in serine/threonine-protein kinases, tyrosine-protein kinases and dual specificity protein kinases. Eukaryotic protein kinases are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common with both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of the catalytic domain there is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. In the central part of the catalytic domain there is a conserved aspartic acid residue which is important for the catalytic activity of the enzyme. Protein phosphorylation, which plays a key role in most cellular activities, is a reversible process mediated by protein kinases and phosphoprotein phosphatases. Protein kinases catalyse the transfer of the gamma phosphate from nucleotide triphosphates (often ATP) to one or more amino acid residues in a protein substrate side chain, resulting in a conformational change affecting protein function. Phosphoprotein phosphatases catalyse the reverse process. Protein kinases fall into three broad classes, characterised with respect to substrate specificity: Serine/threonine-protein kinases Tyrosine-protein kinases Dual specificity protein kinases (e.g. MEK -phosphorylates both Thr and Tyr on target proteins) Protein kinase function is evolutionarily conserved from Escherichia coli to human. Protein kinases play a role in a multitude of cellular processes, including division, proliferation, apoptosis, and differentiation. Phosphorylation usually results in a functional change of the target protein by changing enzyme activity, cellular location, or association with other proteins. The catalytic subunits of protein kinases are highly conserved, and several structures have been solved, leading to large screens to develop kinase-specific inhibitors for the treatments of a number of diseases. | No verified residues in this structure |
| Predicted superfamily: CATH 3.30.60.20AF-P15056-F1-model_v4_TED03 | 236–290 | TEDdomainTED · PredictedMedium consensus TED predicts a match to CATH superfamily 3.30.60.20. A superfamily match suggests an evolutionary relationship; it does not establish this domain's specific function. Full source descriptionTED predicts a match to CATH superfamily 3.30.60.20. A superfamily match suggests an evolutionary relationship; it does not establish this domain's specific function. No descriptive name is available in the bundled CATH names snapshot. Source model: AF-P15056-F1-model_v4 · version 4. Source-model pLDDT: 82.2804. Confidence describes the originating prediction, not this experimental structure. CATH 3.30.60.20 · H. A structural classification does not establish a specific function. Source entry ↗ | No verified residues in this structure |
UniProt domains, repeats & motifs 2
Scroll across the table for evidence and actions.
2 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Domain | 155–227 | RBD | Sequence analysis Evidence & references
| No verified residues in this structure |
| Domain | 457–717 | Protein kinase | Sequence analysis Evidence & references
| No verified residues in this structure |
Functional sites 14
Scroll across the table for evidence and actions.
14 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Zinc finger | 234–280 | Phorbol-ester/DAG-type | Sequence analysis Evidence & references
| No verified residues in this structure |
| Active site | 576 | Proton acceptor | Sequence analysis Evidence & references
| No verified residues in this structure |
| Binding site | 235 | Binding site | By similarity Evidence & references
| No verified residues in this structure |
| Binding site | 248 | Binding site | By similarity Evidence & references
| No verified residues in this structure |
| Binding site | 251 | Binding site | By similarity Evidence & references
| No verified residues in this structure |
| Binding site | 261 | Binding site | By similarity Evidence & references
| No verified residues in this structure |
| Binding site | 264 | Binding site | By similarity Evidence & references
| No verified residues in this structure |
| Binding site | 269 | Binding site | By similarity Evidence & references
| No verified residues in this structure |
| Binding site | 272 | Binding site | By similarity Evidence & references
| No verified residues in this structure |
| Binding site | 280 | Binding site | By similarity Evidence & references
| No verified residues in this structure |
| Binding site | 463–471 | Binding site | Sequence analysis Evidence & references
| No verified residues in this structure |
| Binding site | 483 | Binding site | Sequence analysis Evidence & references
| No verified residues in this structure |
| Site | 380–381 | Breakpoint for translocation to form KIAA1549-BRAF fusion protein | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Site | 438–439 | Breakpoint for translocation to form KIAA1549-BRAF fusion protein | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
Sequence regions 6
Scroll across the table for evidence and actions.
6 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Region | 1–38 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 308–454 | Disordered | Evidence & references
| No verified residues in this structure |
| Compositional bias | 1–13 | Gly residues | Evidence & references
| No verified residues in this structure |
| Compositional bias | 314–341 | Low complexity | Evidence & references
| No verified residues in this structure |
| Compositional bias | 348–363 | Basic and acidic residues | Evidence & references
| No verified residues in this structure |
| Compositional bias | 423–447 | Basic and acidic residues | Evidence & references
| No verified residues in this structure |
Sequence & Isoforms
Sequence & isoforms
UniProt’s canonical sequence is its selected representative. It is not necessarily the dominant isoform in every tissue.
The mass describes this unmodified source sequence, not every mature or modified product.
MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVHSource isoform notes & selection
Isoform sequence differences 0
No annotation is recorded in this UniProt entry.
Sequence conflicts & cautions 1
Scroll across the table for evidence and actions.
1 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Sequence conflict | 766 | in Ref. 11; AAA96495 H → D | Curator inference Evidence & references
| No verified residues in this structure |
Source sequence: AAD43193.1
Evidence & references
- ECO:0000305
Source sequence: CAQ43111.1
Extended N-terminus.
Evidence & references
- ECO:0000305
Source sequence: CAQ43112.1
Extended N-terminus.
Evidence & references
- ECO:0000305
Source sequence: CAQ43113.1
Extended N-terminus.
Evidence & references
- ECO:0000305
Source sequence: CAQ43114.1
Extended N-terminus.
Evidence & references
- ECO:0000305
Source sequence: CAQ43115.1
Extended N-terminus.
Evidence & references
- ECO:0000305
Source sequence: CAQ43116.1
Extended N-terminus.
Evidence & references
- ECO:0000305
Recorded secondary structure 51
Scroll across the table for evidence and actions.
51 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Helix | 43–68 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 76–103 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 156–161 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 162–164 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 165–170 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 177–186 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 187–189 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 192–194 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 195–199 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 205–208 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 214–217 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 221–226 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 237–241 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 249–251 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 256–261 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 262–264 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 273–275 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 448–450 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 454–456 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 458–466 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 469–484 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 487–489 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 492–505 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 510–514 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 516–520 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 522–524 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 526–530 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 534–536 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 539–543 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 546–549 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 550–569 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 579–581 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 582–585 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 586–588 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 589–592 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 598–603 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 604–607 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 609–612 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 614–619 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 622–626 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 629–631 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 635–651 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 655–658 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 662–671 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 678–680 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 683–685 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 687–696 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 701–703 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 707–721 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 723–726 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 731–734 | Helix | Evidence & references
| No verified residues in this structure |
Homologs
OMA orthologs
Evolutionary relationships assigned by OMA, kept separate from sequence clusters. “1:1” describes an orthology relationship, not percentage identity.
Recorded preview of up to 12 orthologs; not an exhaustive list. Entries without a verified UniProt mapping open their OMA record.
Sources & References
Scientific descriptions and evidence come from the named sources. Atlas assembles the presentation and verifies residue mappings; it does not independently curate these claims.
Source dates & provenance
- UniProt / The UniProt Consortium ↗ · 2026-11-09T11:40:21.311919+00:00
- InterPro / EMBL-EBI and the member sources identified in the annotations ↗ · 2026-11-09T11:40:23.343886+00:00
- AlphaFold DB / DeepMind Technologies Limited / EMBL-EBI ↗ · 2026-11-09T11:40:25.390415+00:00
- TED / Lau et al. (2024), University College London ↗ · 2026-11-09T11:52:27.252591+00:00
- UniProt / The UniProt Consortium ↗ · 2026-11-09T11:40:21.311919+00:00
- InterPro / EMBL-EBI and the member sources identified in the annotations ↗ · 2026-11-09T11:40:23.343886+00:00
- AlphaFold DB / DeepMind Technologies Limited / EMBL-EBI ↗ · 2026-11-09T11:40:25.390415+00:00
- TED / Lau et al. (2024), University College London ↗ · 2026-11-09T11:52:27.252591+00:00
- UniProt overview ↗ · 2026-11-10T20:42:45.956070+00:00
- omabrowser.org ↗ · 2026-11-10T21:11:42.876461+00:00
- omabrowser.org ↗ · 2026-11-10T21:11:42.935352+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:43.198161+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:43.231394+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:43.374017+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:44.185186+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:44.284933+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:44.321110+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:45.837472+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:45.996259+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:11:49.018214+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:11:49.053151+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:11:51.327802+00:00
Recorded 2026-11-10. Source dates and identifiers are retained below.
Publications in this UniProt entry
1992 · Mol. Cell. Biol.
PubMed 1508179 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA]; PARTIAL PROTEIN SEQUENCE; FUNCTION; PHOSPHORYLATION AT THR-373
Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R., Morrison D.K.
JAN-2004 ·
Scope & authors
SEQUENCE REVISION TO 31-33
Albert S., Wixler L., Rapp U.R.
MAR-2008 ·
Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA]
2003 · Science
PubMed 12690205 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., Adams M.D., Tsui L.-C.
All source publications (46)
2003 · Nature
PubMed 12853948 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., Wilson R.K.
2004 · Genome Res.
PubMed 15489334 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]
1992 · Oncogene
PubMed 1630826 ↗Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200
Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.
DEC-2008 ·
Scope & authors
PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354; 361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698; 702-719; 727-735 AND 753-766; CLEAVAGE OF INITIATOR METHIONINE; ACETYLATION AT ALA-2; PHOSPHORYLATION AT SER-365; THR-396; SER-399; THR-401 AND SER-729; IDENTIFICATION BY MASS SPECTROMETRY
Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.
1990 · Oncogene
PubMed 2284096 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] OF 117-766
Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.
2008 · Cancer Res.
PubMed 18974108 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] OF 381-766; DISEASE; CHROMOSOMAL REARRANGEMENT
Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., Ichimura K., Collins V.P.
1988 · Mol. Cell. Biol.
PubMed 3043188 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] OF 439-766
Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.
2001 · J. Biol. Chem.
PubMed 11410590 ↗Scope & authors
PHOSPHORYLATION AT SER-365 BY SGK1
Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.
2006 · Nat. Biotechnol.
PubMed 16964243 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.
2008 · Mol. Cell
PubMed 18691976 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., Greff Z., Keri G., Stemmann O., Mann M.
2008 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 18669648 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447 AND SER-729; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P.
2009 · J. Biol. Chem.
PubMed 19710016 ↗Scope & authors
SUBUNIT; INTERACTION WITH DGKH; SUBCELLULAR LOCATION; PHOSPHORYLATION AT THR-753 BY MAPK1
Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., Sakane F.
2009 · Sci. Signal.
PubMed 19690332 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K.
2010 · Nat. Cell Biol.
PubMed 21102438 ↗Scope & authors
INTERACTION WITH AKAP13; MAP2K1 AND KSR1
Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., Davis R.J., Scott J.D.
2010 · Sci. Signal.
PubMed 20068231 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.
2011 · Nature
PubMed 21441910 ↗Scope & authors
INTERACTION WITH KSR2; SUBUNIT; CATALYTIC ACTIVITY; FUNCTION; MUTAGENESIS OF LYS-483
Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., Shokat K.M., Barford D.
2011 · Sci. Signal.
PubMed 21917714 ↗Scope & authors
INTERACTION WITH PRMT5; METHYLATION AT ARG-671; CHARACTERIZATION OF VARIANT CRC GLU-600; MUTAGENESIS OF ARG-671
Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., Avila M.A., Recio J.A.
2011 · Sci. Signal.
PubMed 21406692 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.
2012 · J. Biol. Chem.
PubMed 22628551 ↗Scope & authors
UBIQUITINATION BY RNF149
Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A., Kim S.M., Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K., Lee J.S., Kim T.W.
2013 · J. Proteome Res.
PubMed 23186163 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401; SER-446 AND SER-729; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., Mohammed S.
2013 · Sci. Rep.
PubMed 23907581 ↗Scope & authors
UBIQUITINATION AT LYS-578; MUTAGENESIS OF LYS-578
An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J., Shi Z., Xu G., Li G., Yang J., Zhang H.
2014 · J. Proteomics
PubMed 24275569 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., Ye M., Zou H.
2016 · Nat. Commun.
PubMed 27353360 ↗Scope & authors
INTERACTION WITH FNIP1 AND FNIP2
Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., Bratslavsky G., Mollapour M.
2019 · Front. Physiol.
PubMed 31024343 ↗Scope & authors
INTERACTION WITH YWHAZ
Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.
2022 · Nat. Commun.
PubMed 36402789 ↗Scope & authors
FUNCTION; SUBUNIT
McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y., Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A., Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E., Garcia-Patos V., Recio J.A.
2022 · Nature
PubMed 35768504 ↗Scope & authors
DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX
Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.
2022 · Nature
PubMed 35830882 ↗Scope & authors
DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX
Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., Eck M.J., Tordella L., Thoma C.R., King D.A.
2008 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 18287029 ↗Scope & authors
X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH INHIBITOR
Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G.
2018 · Nature
PubMed 29433126 ↗Scope & authors
X-RAY CRYSTALLOGRAPHY; FUNCTION; CATALYTIC ACTIVITY; ACTIVITY REGULATION; INTERACTION WITH KSR1; KSR2; MAP2K1 AND MAP2K2; MUTAGENESIS OF MET-53; LYS-88; ARG-509 AND ILE-666
Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., Kurinov I., Sicheri F., Therrien M.
2002 · Cancer Res.
PubMed 12460919 ↗Scope & authors
VARIANTS LNCR VAL-466 AND ARG-597
Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.
2002 · Nature
PubMed 12068308 ↗Scope & authors
VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469; GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND ASP-600; CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469; VAL-597 AND GLU-600
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
2002 · Nature
PubMed 12198537 ↗Scope & authors
VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601
Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E.
2003 · Br. J. Cancer
PubMed 14612909 ↗Scope & authors
VARIANTS NHL ALA-469; ARG-469 AND GLY-594
Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y., Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.
2003 · Cancer Res.
PubMed 14500344 ↗Scope & authors
CHARACTERIZATION OF VARIANT MELANOMA GLU-600
Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A.
2006 · Nat. Genet.
PubMed 16474404 ↗Scope & authors
VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501 AND ASP-581
Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., Matsubara Y.
2006 · Science
PubMed 16959974 ↗Scope & authors
VARIANT [LARGE SCALE ANALYSIS] GLU-600
Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E.
2006 · Science
PubMed 16439621 ↗Scope & authors
VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596
Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., McCormick F., Rauen K.A.
2007 · Nature
PubMed 17344846 ↗Scope & authors
VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581; ARG-596; ARG-597; VAL-597 AND GLU-600
Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.
2008 · Clin. Genet.
PubMed 18042262 ↗Scope & authors
VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468; GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595
Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A., Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C., Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B., Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S., Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.
2009 · Hum. Mutat.
PubMed 19206169 ↗Scope & authors
VARIANT LPRD3 PRO-241; VARIANTS NS7 ARG-241; MET-241; CYS-531 AND VAL-597; VARIANTS CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709
Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C., Pantaleoni F., Scioletti A.P., Esposito G., Cordeddu V., Lepri F., Petrangeli V., Dentici M.L., Mancini G.M., Selicorni A., Rossi C., Mazzanti L., Marino B., Ferrero G.B., Silengo M.C., Memo L., Stanzial F., Faravelli F., Stuppia L., Puxeddu E., Gelb B.D., Dallapiccola B., Tartaglia M.
2013 · Nat. Genet.
PubMed 23263490 ↗Scope & authors
VARIANT CRC GLU-600
Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., Houlston R.S., Tomlinson I.
2014 · Front. Oncol.
PubMed 24455489 ↗Scope & authors
VARIANT CRC GLU-600
D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H., Furneaux C.E., During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.
Atlas of Genetics and Cytogenetics in Oncology and Haematology ↗
Annotation coverage audit
Every recorded UniProt comment and feature has a destination in this page. GO, Atlas annotations and interaction rows retain their separate source counts.
174 source comments and features accounted for.
View annotation inventory
| Source record | Type | Section |
|---|---|---|
| FUNCTION:0 | FUNCTION | function |
| CATALYTIC ACTIVITY:0 | CATALYTIC ACTIVITY | function |
| CATALYTIC ACTIVITY:1 | CATALYTIC ACTIVITY | function |
| COFACTOR:0 | COFACTOR | function |
| ACTIVITY REGULATION:0 | ACTIVITY REGULATION | function |
| SUBUNIT:0 | SUBUNIT | interactions |
| INTERACTION:0 | INTERACTION | interactions |
| SUBCELLULAR LOCATION:0 | SUBCELLULAR LOCATION | location |
| TISSUE SPECIFICITY:0 | TISSUE SPECIFICITY | expression |
| PTM:0 | PTM | processing |
| PTM:1 | PTM | processing |
| PTM:2 | PTM | processing |
| DISEASE:0 | DISEASE | disease |
| DISEASE:1 | DISEASE | disease |
| DISEASE:2 | DISEASE | disease |
| DISEASE:3 | DISEASE | disease |
| DISEASE:4 | DISEASE | disease |
| DISEASE:5 | DISEASE | disease |
| DISEASE:6 | DISEASE | disease |
| DISEASE:7 | DISEASE | disease |
| SIMILARITY:0 | SIMILARITY | domains |
| SEQUENCE CAUTION:0 | SEQUENCE CAUTION | sequence |
| SEQUENCE CAUTION:1 | SEQUENCE CAUTION | sequence |
| SEQUENCE CAUTION:2 | SEQUENCE CAUTION | sequence |
| SEQUENCE CAUTION:3 | SEQUENCE CAUTION | sequence |
| SEQUENCE CAUTION:4 | SEQUENCE CAUTION | sequence |
| SEQUENCE CAUTION:5 | SEQUENCE CAUTION | sequence |
| SEQUENCE CAUTION:6 | SEQUENCE CAUTION | sequence |
| WEB RESOURCE:0 | WEB RESOURCE | sources |
| feature-0 | Initiator methionine | processing |
| feature-1 | Chain | processing |
| feature-2 | Domain | domains |
| feature-3 | Domain | domains |
| feature-4 | Zinc finger | domains |
| feature-5 | Region | domains |
| feature-6 | Region | domains |
| feature-7 | Compositional bias | domains |
| feature-8 | Compositional bias | domains |
| feature-9 | Compositional bias | domains |
| feature-10 | Compositional bias | domains |
| feature-11 | Active site | domains |
| feature-12 | Binding site | domains |
| feature-13 | Binding site | domains |
| feature-14 | Binding site | domains |
| feature-15 | Binding site | domains |
| feature-16 | Binding site | domains |
| feature-17 | Binding site | domains |
| feature-18 | Binding site | domains |
| feature-19 | Binding site | domains |
| feature-20 | Binding site | domains |
| feature-21 | Binding site | domains |
| feature-22 | Site | domains |
| feature-23 | Site | domains |
| feature-24 | Modified residue | processing |
| feature-25 | Modified residue | processing |
| feature-26 | Modified residue | processing |
| feature-27 | Modified residue | processing |
| feature-28 | Modified residue | processing |
| feature-29 | Modified residue | processing |
| feature-30 | Modified residue | processing |
| feature-31 | Modified residue | processing |
| feature-32 | Modified residue | processing |
| feature-33 | Modified residue | processing |
| feature-34 | Modified residue | processing |
| feature-35 | Modified residue | processing |
| feature-36 | Modified residue | processing |
| feature-37 | Modified residue | processing |
| feature-38 | Cross-link | processing |
| feature-39 | Natural variant | disease |
| feature-40 | Natural variant | disease |
| feature-41 | Natural variant | disease |
| feature-42 | Natural variant | disease |
| feature-43 | Natural variant | disease |
| feature-44 | Natural variant | disease |
| feature-45 | Natural variant | disease |
| feature-46 | Natural variant | disease |
| feature-47 | Natural variant | disease |
| feature-48 | Natural variant | disease |
| feature-49 | Natural variant | disease |
| feature-50 | Natural variant | disease |
| feature-51 | Natural variant | disease |
| feature-52 | Natural variant | disease |
| feature-53 | Natural variant | disease |
| feature-54 | Natural variant | disease |
| feature-55 | Natural variant | disease |
| feature-56 | Natural variant | disease |
| feature-57 | Natural variant | disease |
| feature-58 | Natural variant | disease |
| feature-59 | Natural variant | disease |
| feature-60 | Natural variant | disease |
| feature-61 | Natural variant | disease |
| feature-62 | Natural variant | disease |
| feature-63 | Natural variant | disease |
| feature-64 | Natural variant | disease |
| feature-65 | Natural variant | disease |
| feature-66 | Natural variant | disease |
| feature-67 | Natural variant | disease |
| feature-68 | Natural variant | disease |
| feature-69 | Natural variant | disease |
| feature-70 | Natural variant | disease |
| feature-71 | Natural variant | disease |
| feature-72 | Natural variant | disease |
| feature-73 | Natural variant | disease |
| feature-74 | Natural variant | disease |
| feature-75 | Natural variant | disease |
| feature-76 | Natural variant | disease |
| feature-77 | Natural variant | disease |
| feature-78 | Natural variant | disease |
| feature-79 | Natural variant | disease |
| feature-80 | Natural variant | disease |
| feature-81 | Natural variant | disease |
| feature-82 | Natural variant | disease |
| feature-83 | Natural variant | disease |
| feature-84 | Natural variant | disease |
| feature-85 | Natural variant | disease |
| feature-86 | Mutagenesis | disease |
| feature-87 | Mutagenesis | disease |
| feature-88 | Mutagenesis | disease |
| feature-89 | Mutagenesis | disease |
| feature-90 | Mutagenesis | disease |
| feature-91 | Mutagenesis | disease |
| feature-92 | Mutagenesis | disease |
| feature-93 | Sequence conflict | sequence |
| feature-94 | Helix | sequence |
| feature-95 | Helix | sequence |
| feature-96 | Beta strand | sequence |
| feature-97 | Turn | sequence |
| feature-98 | Beta strand | sequence |
| feature-99 | Helix | sequence |
| feature-100 | Turn | sequence |
| feature-101 | Helix | sequence |
| feature-102 | Beta strand | sequence |
| feature-103 | Beta strand | sequence |
| feature-104 | Helix | sequence |
| feature-105 | Beta strand | sequence |
| feature-106 | Beta strand | sequence |
| feature-107 | Turn | sequence |
| feature-108 | Beta strand | sequence |
| feature-109 | Turn | sequence |
| feature-110 | Helix | sequence |
| feature-111 | Helix | sequence |
| feature-112 | Helix | sequence |
| feature-113 | Beta strand | sequence |
| feature-114 | Beta strand | sequence |
| feature-115 | Beta strand | sequence |
| feature-116 | Helix | sequence |
| feature-117 | Beta strand | sequence |
| feature-118 | Beta strand | sequence |
| feature-119 | Beta strand | sequence |
| feature-120 | Beta strand | sequence |
| feature-121 | Beta strand | sequence |
| feature-122 | Helix | sequence |
| feature-123 | Helix | sequence |
| feature-124 | Helix | sequence |
| feature-125 | Helix | sequence |
| feature-126 | Beta strand | sequence |
| feature-127 | Turn | sequence |
| feature-128 | Beta strand | sequence |
| feature-129 | Helix | sequence |
| feature-130 | Beta strand | sequence |
| feature-131 | Helix | sequence |
| feature-132 | Helix | sequence |
| feature-133 | Helix | sequence |
| feature-134 | Beta strand | sequence |
| feature-135 | Helix | sequence |
| feature-136 | Turn | sequence |
| feature-137 | Helix | sequence |
| feature-138 | Helix | sequence |
| feature-139 | Beta strand | sequence |
| feature-140 | Helix | sequence |
| feature-141 | Helix | sequence |
| feature-142 | Helix | sequence |
| feature-143 | Beta strand | sequence |
| feature-144 | Helix | sequence |